TrialBMC cancer2021

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.

Thomas Powles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.